Ratings Solasto Corporation

Equities

6197

JP3436250009

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-09 EDT			5-day change	1st Jan Change
498 ^JPY	0.00%		+0.61%	-19.16%

04-22	Solasto's Occupancy Rate Slips in March	MT
03-21	Solasto's Number of Facility Residents Up Nearly 14.7% in February	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's attractive earnings multiples are brought to light by a P/E ratio at 8.93 for the current year.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.42 for the 2024 fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company does not generate enough profits, which is an alarming weak point.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
SOLASTO CORPORATION	-19.16%	295M	-
HCA HEALTHCARE, INC.	+18.92%	81.04B	C+
CVS HEALTH CORPORATION	-29.48%	68.93B	B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.65%	29.59B	C+
FRESENIUS SE & CO. KGAA	-0.14%	17.24B	A-
LABORATORY CORPORATION OF AMERICA HOLDINGS	-9.30%	16.99B	B
QUEST DIAGNOSTICS INCORPORATED	+0.20%	15.12B	A-
REDE D'OR SÃO LUIZ S.A.	+5.25%	13.09B	B-
TENET HEALTHCARE CORPORATION	+68.96%	12B	C+
EUROFINS SCIENTIFIC SE	-2.88%	11.94B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes